Specialty Pharmacy Pipeline

Drugs to Watch

Anticipated Launches | Q2 2021 – Q3 2021
## Specialty Pharmacy Pipeline Drugs to Watch
### Anticipated Launches – 2nd Quarter 2021 to 3rd Quarter 2021

<table>
<thead>
<tr>
<th>Therapeutic Category</th>
<th>Product Name, Route of Administration and Manufacturer</th>
<th>Proposed Indication¹</th>
<th>Phase of Study¹</th>
<th>Disease Prevalence and Background</th>
<th>Select Available U.S. Food and Drug Administration (FDA) Approved Therapies</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atopic Dermatitis (AD)</td>
<td>abrocitinib oral Pfizer</td>
<td>The treatment of moderate-to-severe AD in patients aged 12 years and older</td>
<td>Pending FDA approval 07/27/2021</td>
<td>AD, also referred to as eczema, is a chronic inflammatory disorder affecting the skin. Common symptoms include widespread areas of dry skin, itching, and red rashes. Scratching may lead to oozing and crusting as well as thickening and hardening of the skin. Skin infections may also occur.</td>
<td>Dupixent (dupilumab) SC</td>
<td>Abrocitinib was granted Breakthrough Therapy designation and will provide an oral therapy option for moderate-to-severe AD. Tralokinumab will provide an additional self-injected therapy option. Both agents will be included in Specialty Guideline Management. <strong>Anticipated impact:</strong> Replacement spend, pharmacy benefit</td>
</tr>
<tr>
<td></td>
<td>tralokinumab subcutaneous (SC) injection LEO Pharma</td>
<td>The treatment of moderate-to-severe AD in adults</td>
<td>Pending FDA approval 05/09/2021</td>
<td>AD affects 10 to 20% of children and 5 to 10% of adults.² Approximately 40% of patients have moderate-to-severe disease.³</td>
<td>Numerous topical therapies may be used</td>
<td></td>
</tr>
<tr>
<td>Growth Hormone Deficiency (GHD)</td>
<td>lonapegsomatropin SC injection Ascendis Pharmaceuticals</td>
<td>The treatment of GHD in pediatrics</td>
<td>Pending FDA approval 06/25/2021</td>
<td>GHD is a rare disorder which is characterized by the insufficient secretion of growth hormone, an essential hormone which maintains normal body structure and metabolism. Signs and symptoms of GHD may include slow growth, low blood sugar levels, and poor development of bones in the middle face. GHD occurs in approximately 1 in every 3,800 infants.⁴</td>
<td>SC, daily administered somatropin (recombinant human growth hormone) agents: Genotropin, Humatrope, Norditropin, Nutropin AQ, Omnitrope, Saizen, Zomacton Long-acting somatropin agent: Sogroya (somapacitan-beco) – indicated for adult GHD</td>
<td>Lonapegsomatropin is an additional once weekly, SC, self-administered growth hormone product that will offer a less frequent administration schedule compared to currently available therapies for pediatric GHD. It will be included in Specialty Guideline Management. <strong>Anticipated impact:</strong> Replacement spend, pharmacy benefit</td>
</tr>
</tbody>
</table>

¹ Proposed indication and phase of study as of the date of publication. 
² AD affects 10 to 20% of children and 5 to 10% of adults. 
³ Approximately 40% of patients have moderate-to-severe disease. 
⁴ GHD occurs in approximately 1 in every 3,800 infants. 

The information contained herein is compiled from independent clinical sources and is provided for informational purposes only. Due to circumstances beyond CVS Caremark’s control, prospective drug launch dates are subject to change without notice. This information should not be solely relied upon for decision-making purposes. This document includes products that may fall under a general specialty drug benefit. All products contained herein may not be provided by CVS Specialty Pharmacy. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.
## Specialty Pharmacy Pipeline Drugs to Watch
### Anticipated Launches – 2nd Quarter 2021 to 3rd Quarter 2021

<table>
<thead>
<tr>
<th>Therapeutic Category</th>
<th>Product Name, Route of Administration and Manufacturer</th>
<th>Proposed Indication</th>
<th>Phase of Study</th>
<th>Disease Prevalence and Background</th>
<th>Select Available U.S. Food and Drug Administration (FDA) Approved Therapies</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lysosomal Storage Disorders (LSDs)</td>
<td>arimoclomol oral Orphazyme</td>
<td>The treatment of Niemann-Pick type C (NPC) disease</td>
<td>Pending FDA approval 06/17/2021</td>
<td>NPC is a rare, progressive LSD which results in an abnormal accumulation of cholesterol and other fats in various tissues. This accumulation of lipids within the body causes damage to various organs including the liver, spleen, and brain, as well as loss of cognitive skills, seizures, and difficulty with speech, swallowing, and feeding. The incidence of NPC is 1 in 100,000 live births. In the U.S. and Europe, there are approximately 1,100 diagnosed patients with NPC.</td>
<td>There are no FDA approved treatments for NPC in the U.S. Zavesca (miglustat) is approved in Europe for NPC and is approved in the U.S. for Gaucher disease.</td>
<td>Arimoclomol was granted Breakthrough Therapy designation and will be the first FDA approved agent for treatment of NPC disease. It will be included in Specialty Guideline Management. Anticipated impact: New spend, pharmacy benefit</td>
</tr>
<tr>
<td>Lysosomal Storage Disorders (LSDs)</td>
<td>avalglucosidase alfa IV Genzyme/ Sanofi</td>
<td>The treatment of Pompe disease (glycogen storage disease type II)</td>
<td>Pending FDA approval 05/18/2021</td>
<td>Pompe disease is a rare, inherited LSD that leads to accumulation of glycogen, a complex sugar, in muscles as well as other organs and tissues. In the most severe type, infantile-onset Pompe disease, symptoms generally begin a few months after birth and include muscle weakness, decreased muscle tone, heart defects, failure to thrive, and breathing difficulties. If untreated, infantile-onset Pompe disease results in death within the first year of life. Other types of Pompe disease generally lead to less severe symptoms and longer life span. Pompe disease affects about 1 in 40,000 people in the U.S.</td>
<td>Lumizyme (alglucosidase alfa) IV</td>
<td>Avalglucosidase alfa was granted Breakthrough Therapy designation and will provide an alternative therapy option for Pompe disease. It will be included in Specialty Guideline Management. Anticipated impact: Replacement spend, medical benefit</td>
</tr>
</tbody>
</table>
## Specialty Pharmacy Pipeline Drugs to Watch
### Anticipated Launches – 2nd Quarter 2021 to 3rd Quarter 2021

<table>
<thead>
<tr>
<th>Therapeutic Category</th>
<th>Product Name, Route of Administration and Manufacturer¹</th>
<th>Proposed Indication¹</th>
<th>Phase of Study¹</th>
<th>Disease Prevalence and Background</th>
<th>Select Available U.S. Food and Drug Administration (FDA) Approved Therapies</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lysosomal Storage Disorders (LSDs) - continued</td>
<td>pegunigalsidase alfa IV Chiesi USA/ Protalix BioTherapeutics</td>
<td>The treatment of Fabry disease in adults</td>
<td>Pending FDA approval 04/27/2021</td>
<td>Fabry disease is a rare, inherited disorder that prevents the body from making alpha-galactosidase, which is needed to break down fatty substances. As a result of the accumulation of fatty substances, blood vessels are narrowed which affects the skin, kidney, heart, brain, and nervous system. Life-threatening complications such as arrhythmias, heart attack, renal failure, and strokes can occur. Fabry disease affects an estimated 1 in 40,000 to 60,000 males. It also affects females, but the incidence is unknown. Males are typically more severely affected than females.²</td>
<td>Fabrazyme (agalsidase beta) IV Galafold (migalastat) oral - limited to those with an amenable genetic variation</td>
<td>Pegunigalsidase alfa could provide an alternative treatment option for Fabry disease. It will be included in Specialty Guideline Management. <strong>Anticipated impact:</strong> Replacement spend, medical benefit</td>
</tr>
<tr>
<td>Neurological Disorders</td>
<td>Aduhelm (aducanumab) IV Biogen/Eisai</td>
<td>The treatment of early Alzheimer’s disease (AD), also referred to as mild cognitive impairment due to AD</td>
<td>Pending FDA approval 06/07/2021</td>
<td>AD is a progressive brain disorder that gradually leads to dementia, also referred to as cognitive impairment (loss of memory and thinking and reasoning skills). In early AD, patients experience altered memory and thinking but are able to perform activities of daily living. As the disease progresses, patients experience memory loss, confusion, and difficulty in completing tasks. Ultimately, patients lose the ability to communicate and care for themselves, and generally become bedbound.¹⁰ AD is the most common cause of dementia. An estimated 4.5 million people in the U.S. have mild cognitive impairment due to AD.¹¹</td>
<td>None; current symptomatic therapies are indicated for patients with established AD dementia.</td>
<td>If approved, Aduhelm will provide the first disease-modifying treatment option for patients with early AD. It will be included in Specialty Guideline Management. In November 2020, the Peripheral and Central Nervous System Advisory Committee voted 8 to 1 that a clinical trial did not provide strong evidence of the efficacy of Aduhelm. <strong>Anticipated impact:</strong> Incremental spend, medical benefit</td>
</tr>
</tbody>
</table>

---

¹ CVS Caremark Pipeline Services
² ©2021 CVS Health and/or one of its affiliates. All rights reserved.
³ 75-22161A 041521
### Specialty Pharmacy Pipeline Drugs to Watch
#### Anticipated Launches – 2nd Quarter 2021 to 3rd Quarter 2021

<table>
<thead>
<tr>
<th>Therapeutic Category</th>
<th>Product Name, Route of Administration and Manufacturer</th>
<th>Proposed Indication</th>
<th>Phase of Study</th>
<th>Disease Prevalence and Background</th>
<th>Select Available U.S. Food and Drug Administration (FDA) Approved Therapies</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral Oncology</td>
<td>sotorasib oral Amgen</td>
<td>The treatment of KRAS p.G12C mutant advanced non-small cell lung cancer (NSCLC) following at least one prior systemic therapy in adults</td>
<td>Pending FDA approval 08/16/2021</td>
<td>Lung cancer is the second most common cancer and the leading cause of cancer death among men and women in the U.S. Approximately 558,000 people are living with lung cancer. NSCLC is the most common type of lung cancer, accounting for 84% of all cases. KRAS p.G12C mutations occur in approximately 13% of NSCLC patients. Presence of these mutations is prognostic for poor survival and is often associated with resistance to targeted therapies. Sotorasib was granted Breakthrough Therapy designation and will be the first FDA approved agent targeting KRAS mutations for NSCLC. It will be included in Specialty Guideline Management. <strong>Anticipated impact:</strong> Replacement spend, shift to pharmacy benefit</td>
<td>Various IV agents used off-label, including: Cyramza (ramucirumab) + docetaxel, Keytruda (pembrolizumab), Opdivo (nivolumab), Tecentriq (atezolizumab), conventional chemotherapy</td>
<td></td>
</tr>
<tr>
<td>Paroxysmal Nocturnal Hemoglobinuria (PNH)</td>
<td>pegcetacoplan SC injection Apellis Pharmaceuticals</td>
<td>The treatment of PNH</td>
<td>Pending FDA approval 05/14/2021</td>
<td>PNH is an acquired disorder in which defective blood cells are produced but are destroyed prematurely. Destruction of red blood cells, or hemolysis, leads to dark colored urine caused by elimination of hemoglobin into the urine. Chronic hemolysis can lead to other signs and symptoms of PNH including fatigue, rapid heartbeat, chest pain, and shortness of breath. Other complications include blood clots, kidney disease, and infection. PNH is estimated to affect 1 to 5 per million people. Pegcetacoplan will provide a self-administered treatment option for patients with PNH. It will be included in Specialty Guideline Management. <strong>Anticipated impact:</strong> Replacement spend, shift to pharmacy benefit</td>
<td>Soliris (eculizumab) IV, Ultomiris (ravulizumab-cwvz) IV</td>
<td></td>
</tr>
</tbody>
</table>

The information contained herein is compiled from independent clinical sources and is provided for informational purposes only. Due to circumstances beyond CVS Caremark’s control, prospective drug launch dates are subject to change without notice. This information should not be solely relied upon for decision-making purposes. This document includes products that may fall under a general specialty drug benefit. All products contained herein may not be provided by CVS Specialty Pharmacy. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2021 CVS Health and/or one of its affiliates. All rights reserved.
75-22161A 041521
## Specialty Pharmacy Pipeline Drugs to Watch
Anticipated Launches – 2nd Quarter 2021 to 3rd Quarter 2021

<table>
<thead>
<tr>
<th>Therapeutic Category</th>
<th>Product Name, Route of Administration and Manufacturer¹</th>
<th>Proposed Indication¹</th>
<th>Phase of Study¹</th>
<th>Disease Prevalence and Background</th>
<th>Select Available U.S. Food and Drug Administration (FDA) Approved Therapies</th>
<th>Comments</th>
</tr>
</thead>
</table>
| Psoriasis            | bimekizumab SC injection UCB                             | The treatment of moderate-to-severe plaque psoriasis | Pending approval 07/15/2021 | Psoriasis is a chronic autoimmune disease primarily affecting the skin and joints. The most common form, plaque psoriasis, causes raised, thick, scaly patches on the skin that often can itch, cause pain, crack, and bleed.¹⁷ | **Topical Agents:** Various products for mild-to-moderate psoriasis  
**Oral Agent:** Otezla (apremilast)  
**SC injectable biologic agents:** Cimzia (certolizumab pegol), Cosentyx (secukinumab), Enbrel (etanercept), Humira (adalimumab), Ilumya (tildrakizumab), Siliq (brodalumab), Skyrizi (risankizumab-rzzaa), Stelara (ustekinumab), Taliz (ixekizumab), Tremfya (guselkumab)  
**IV infused biologic agents:** infliximab (Remicade and biosimilar products: Avsola, Inflectra, Renflexis) | If approved, bimekizumab would provide another subcutaneously administered option for treatment of plaque psoriasis. It will be included in Specialty Guideline Management.  
**Anticipated impact:** Replacement spend, pharmacy benefit |

¹ The information contained herein is compiled from independent clinical sources and is provided for informational purposes only. Due to circumstances beyond CVS Caremark’s control, prospective drug launch dates are subject to change without notice. This information should not be solely relied upon for decision-making purposes. This document includes products that may fall under a general specialty drug benefit. All products contained herein may not be provided by CVS Specialty Pharmacy. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2021 CVS Health and/or one of its affiliates. All rights reserved.

Page 6 of 8
<table>
<thead>
<tr>
<th>Therapeutic Category</th>
<th>Product Name, Route of Administration and Manufacturer¹</th>
<th>Proposed Indication¹</th>
<th>Phase of Study¹</th>
<th>Disease Prevalence and Background</th>
<th>Select Available U.S. Food and Drug Administration (FDA) Approved Therapies</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic Lupus Erythematosus (SLE)</td>
<td>anifrolumab IV AstraZeneca/ Bristol-Myers Squibb</td>
<td>The treatment of moderate-to-severe SLE in adults</td>
<td>Pending approval 07/05/2021</td>
<td>SLE is a chronic autoimmune disorder in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage that can affect various organ systems (e.g., kidneys, brain, heart, skin, joints).²⁰ Approximately 322,000 people in the U.S. have definite or probable SLE. Although SLE affects people of all ages, it is most common in women of childbearing age belonging to minority racial and ethnic groups.²¹ An estimated 28% of patients have moderate-to-severe disease.²²</td>
<td>Oral Agents: hydroxychloroquine Injectable Agents: Benlysta (belimumab) IV, SC</td>
<td>Anifrolumab will provide an additional treatment option for SLE. It will be included in Specialty Guideline Management. Anticipated impact: Replacement impact; medical benefit</td>
</tr>
</tbody>
</table>

¹ RxPipeline, April 2021.

The information contained herein is compiled from independent clinical sources and is provided for informational purposes only. Due to circumstances beyond CVS Caremark’s control, prospective drug launch dates are subject to change without notice. This information should not be solely relied upon for decision-making purposes. This document includes products that may fall under a general specialty drug benefit. All products contained herein may not be provided by CVS Specialty Pharmacy. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

CVS Caremark Pipeline Services

©2021 CVS Health and/or one of its affiliates. All rights reserved.

75-22161A 041521
The information contained herein is compiled from independent clinical sources and is provided for informational purposes only. Due to circumstances beyond CVS Caremark’s control, prospective drug launch dates are subject to change without notice. This information should not be solely relied upon for decision-making purposes. This document includes products that may fall under a general specialty drug benefit. All products contained herein may not be provided by CVS Specialty Pharmacy. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.